SAM
ANIX icon

Strategic Asset Management’s Anixa Biosciences ANIX Stock Holding History

Strategic Asset Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,700
Closed -$10K – 601
2022
Q1 		$10K Buy
+3,700
New +$10.9K 0.01% 372

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Strategic Asset Management's ANIX Position: Q2 2022 in Review

Strategic Asset Management sold out of Anixa Biosciences (ANIX) in Q2 2022, closing a stake of 3,700 shares — an estimated $10K sold.

Strategic Asset Management first reported a position in ANIX in Q1 2022 and held it in 1 quarter. The position peaked at $10K in Q1 2022. 45 funds tracked by Wall St. Rank hold ANIX as of Q2 2022.

  • Strategic Asset Management reported no remaining Anixa Biosciences position as of Q2 2022 after selling out during the quarter.
  • Strategic Asset Management sold 3,700 Anixa Biosciences shares in Q2 2022, an estimated $10K.
  • Strategic Asset Management first reported a position in Anixa Biosciences in Q1 2022 and held it in 1 quarter.
  • Strategic Asset Management's Anixa Biosciences position peaked at $10K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2022.

Based on Strategic Asset Management's 13F filing for Q2 2022, filed 14 Jul 2022.